Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Genmab ( (GMAB) ) has issued an announcement.
On January 23, 2025, Genmab A/S announced the grant of 4,903 restricted stock units and 5,289 warrants to its employees and subsidiaries. This initiative is part of the company’s ongoing efforts to reward and retain talent by providing added incentives aligned with company growth and performance. The restricted stock units and warrants are subject to specific vesting conditions, with units vesting after three years and warrants expiring after seven years. This strategic move underscores Genmab’s commitment to fostering a motivated workforce while reinforcing its position in the competitive biotechnology sector.
More about Genmab
Genmab A/S is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics. The company has a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators. Genmab aims to transform the lives of people with cancer and other serious diseases through its cutting-edge antibody medicines.
YTD Price Performance: 3.81%
Average Trading Volume: 1,249,147
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $13.61B
See more data about GMAB stock on TipRanks’ Stock Analysis page.